JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Nov 2027 → Nov 2028
Primary endpoint removed 6 → 5 primary endpoints
See other at-risk trials from Jacobio Pharmaceuticals Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Nov 2027 to Nov 2028 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 294 → 344 participants
    • Study completion pushed from Feb 2028 to Feb 2029
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Eligibility criteria expanded, about 74 words
    • Secondary endpoints: 5 to 4
    • Study description expanded, about 6 words
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2025 to May 29, 2025
    • Site details revised at 4 of 4 sites
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
Trial Details
NCT Number NCT06973564
Lead Sponsor Jacobio Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Advanced Solid Tumors
Related terms Colorectal Neoplasms, Pancreatic Neoplasms
Enrollment 344 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov